Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...
FiercePharma14h
Pfizer's blockbuster ADC Adcetris nabs FDA approval to treat large B-cell lymphoma
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
How will creators shape brand marketing in 2025?
Street Hearts, Kenyan “confidence queen” and Maxine the Fluffy Corgi take the Ad Age NextGen Marketing Summit stage.
Inflammation-triggering cellular pathway identified as potential new drug target for Alzheimer's disease
A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...
Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...